澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ACTINOGEN MEDICAL LTD

0.042

+0.0012.44%

成交量：179.89萬

成交額：7.53萬

市值：1.45億

市盈率：-8.50

高：0.042

開：0.042

低：0.041

收：0.041

52周最高：0.072

52周最低：0.019

股本：34.62億

流通股本：26.08億

量比：0.51

換手率：0.07%

股息：- -

股息率：- -

每股收益(TTM):-0.005

每股收益(LYR):-0.005

淨資產收益率：-77.47%

總資產收益率：-41.91%

市淨率：7.93

市盈率(LYR):-8.50

資料載入中...

總覽公司新聞資訊公告

概念

醫藥生物股-0.40%

資金流向

資金流入：

資金流出：

新聞資訊

ACTINOGEN MEDICAL LTD的Xanamia關鍵性2B/3期阿爾茨海默試驗完成247名參與者的隨機分組並開始治療

Actinogen：FDA同意僅需進行一項額外的關鍵試驗，採用單一10毫克Xanamem劑量設計對比安慰劑的阿爾茨海默病試驗

Actinogen Medical Ltd計劃於2026年與歐洲藥品管理局就阿爾茨海默病項目舉行會議

Actinogen Medical Ltd與FDA達成協議，就Xanamem阿爾茨海默病藥物未來美國上市審批所需的製造、臨牀及非臨牀活動事宜舉行C類會議

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ACW.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"ACW.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","market":"AU","secType":"STK","nameCN":"ACTINOGEN MEDICAL LTD","latestPrice":0.042,"timestamp":1771564320000,"preClose":0.041,"halted":0,"volume":1798923,"delay":0,"changeRate":0.024390243902439046,"nameEN":"ACTINOGEN MEDICAL LTD","floatShares":2607880613,"shares":3461769000,"eps":-0.004944,"marketStatus":"休市中","change":0.001,"latestTime":"02-20 16:12:00 AEDT","open":0.042,"high":0.042,"low":0.041,"amount":75343,"amplitude":0.02439,"askPrice":0.043,"askSize":116506,"bidPrice":0.042,"bidSize":1905,"shortable":3,"etf":0,"ttmEps":-0.004944,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1771801200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.041,"openAndCloseTimeList":[[1771542000000,1771563600000]],"volumeRatio":0.5074923922480953,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","floatShares":2607880613,"roa":"-41.91%","roe":"-77.47%","lyrEps":-0.004944,"volumeRatio":0.5074923922480953,"shares":3461769000,"dividePrice":0,"high":0.042,"amplitude":0.02439,"preClose":0.041,"low":0.041,"week52Low":0.019,"pbRate":"7.93","psRate":"26.49","week52High":0.072,"institutionHeld":0,"latestPrice":0.042,"committee":-0.967824,"eps":-0.004944,"divideRate":0,"volume":1798923,"delay":0,"ttmEps":-0.004944,"open":0.042,"prevYearClose":0.061,"prevWeekClose":0.041,"prevMonthClose":0.045,"prevQuarterClose":0.061,"fiveDayClose":0.041,"twentyDayClose":0.05,"sixtyDayClose":0.059,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACW.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-10-19","symbol":"ACW.AU","defaultRemindTime":1603062000000,"type":"split","dateTimestamp":1603026000000,"forFactor":98,"toFactor":100,"ratio":0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACW.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACW.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1153606662","title":"ACTINOGEN MEDICAL LTD的Xanamia關鍵性2B/3期阿爾茨海默試驗完成247名參與者的隨機分組並開始治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1153606662","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153606662?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 21:02","pubTimestamp":1766062944,"startTime":"0","endTime":"0","summary":"ACTINOGEN MEDICAL LTD的Xanamia关键性2B/3期阿尔茨海默试验完成247名参与者的随机分组并开始治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"1186330080","title":"Actinogen：FDA同意僅需進行一項額外的關鍵試驗，採用單一10毫克Xanamem劑量設計對比安慰劑的阿爾茨海默病試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1186330080","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186330080?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 20:44","pubTimestamp":1757940254,"startTime":"0","endTime":"0","summary":"Actinogen：FDA同意仅需进行一项额外的关键试验，采用单一10毫克Xanamem剂量设计对比安慰剂的阿尔茨海默病试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"1164379463","title":"Actinogen Medical Ltd計劃於2026年與歐洲藥品管理局就阿爾茨海默病項目舉行會議","url":"https://stock-news.laohu8.com/highlight/detail?id=1164379463","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164379463?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 20:42","pubTimestamp":1757940178,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd计划于2026年与欧洲药品管理局就阿尔茨海默病项目举行会议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"1157388737","title":"Actinogen Medical Ltd與FDA達成協議，就Xanamem阿爾茨海默病藥物未來美國上市審批所需的製造、臨牀及非臨牀活動事宜舉行C類會議","url":"https://stock-news.laohu8.com/highlight/detail?id=1157388737","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157388737?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 20:30","pubTimestamp":1757939416,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd与FDA在C类会议中就其阿尔茨海默病治疗药物Xanamem未来在美国市场获得批准所需的制造、临床和非临床活动达成了协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ACW.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.00401}]}}